



_							
	2017	2018	2019	2020	2021	Period Increase (+) / decrease (-)	% Period Increase (+) / decrease (-)
pooling of high cost drug claim experience for CDIPC member insurance companies							
EP3 plan high cost drug claim experience (certificates exceeding \$10K in drug clain	ns paid annua	lly)					
Quebec ¹						[2017 -	2021]
% of total drug claim dollars paid	34.1%	38.5%	42.4%	44.0%	47.4%	13.2%	38.8%
% plan members with high cost drug claims	1.8%	1.9%	2.2%	2.5%	2.6%	0.8%	46.9%
Pharmacare provinces % of total drug claim dollars paid	10.8%	11.5%	12.5%	13.8%	14.2%	3.4%	31.1%
% plan members with high cost drug claims	0.3%	0.3%	0.3%	0.4%	0.4%	0.1%	42.2%
Non-pharmacare provinces & excluding Quebec							
% of total drug claim dollars paid	29.5%	31.1%	31.9%	34.2%	34.7%	5.2%	17.5%
% plan members with high cost drug claims	1.1%	1.1%	1.2%	1.4%	1.5%	0.4%	37.9%
# of plan members from all of Canada with high-cost drugs when drug paid is ≥ \$10K							
\$10-32.5K	18,220	18,688	20,696	22,960	24,739	6,519	35.8%
\$32.5-65K	3,091	3,293	3,449	3,779	3,904	813	26.3%
\$65-100K \$100-400K	518 249	514 297	555 333	613 399	613 437	95 188	18.3% 75.5%
\$100-400K \$400-620.7K	11	13	21	29	23	12	109.1%
\$620.7-750K	4	4	5	6	7	3	75.0%
\$750K-1M	4	3	3	4	8	4	100.0%
	1	22.014	25,064	27,796	29,737	7,639	500.0% 34.6%
\$1M+ Tota	22,098	22,814	23,004	,	,		
·		3.2%	9.9%	10.9%	7.0%		
Tota						2,041	17.2%
Tota Year over year growth		3.2%	9.9%	10.9%	7.0%	2,041	17.2%
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member ¹		3.2%	9.9%	10.9%	7.0%		
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims	11,850	3.2%	9.9%	10.9%	7.0%	2,041 [2017 - 52	2021]
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same	11,850	3.2% 12,076	9.9%	10.9% 14,464	7.0% 13,891	[2017 -	2021]
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2017	11,850	3.2% 12,076 487	9.9% 13,253 510	10.9% 14,464 529	7.0% 13,891 527	[2017 - 52	2021] 10.9%
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2017 # of drugs new to EP3 claim experience	11,850 475	3.2% 12,076 487	9.9% 13,253 510	10.9% 14,464 529	7.0% 13,891 527	[2017 - 52 [2017 - -40	2021] 10.9% 2021] -48.2%
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2017 # of drugs new to EP3 claim experience Claimed by # plan members	11,850 475 83 167	3.2% 12,076 487 46 656	9.9% 13,253 510 42 1,175	10.9% 14,464 529 46 1,549	7.0% 13,891 527 43 1,750	[2017 - 52 [2017 - -40 1583	2021] 10.9% 2021] -48.2% 947.9%
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2017 # of drugs new to EP3 claim experience	11,850 475	3.2% 12,076 487	9.9% 13,253 510	10.9% 14,464 529	7.0% 13,891 527	[2017 - 52 [2017 - -40	2021] 10.9% 2021] -48.2% 947.9% 745.6%
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2017 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2018	11,850 475 83 167 \$5.7	3.2% 12,076 487 46 656 \$21.4	9.9% 13,253 510 42 1,175 \$33.0 \$28,122	10.9% 14,464 529 46 1,549 \$44.3	7.0% 13,891 527 43 1,750 \$48.2	[2017 - 52	2021] 10.9% 2021] -48.2% 947.9% 745.6% -25.4%
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2017 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2018 # of drugs new to EP3 claim experience	11,850 475 83 167 \$5.7	3.2% 12,076 487 46 656 \$21.4 \$32,459 61	9.9% 13,253 510 42 1,175 \$33.0 \$28,122	10.9% 14,464 529 46 1,549 \$44.3 \$28,599	7.0% 13,891 527 43 1,750 \$48.2 \$25,315	[2017 - 52	2021] 10.9% 2021] -48.2% 947.9% 745.6% -25.4% -2021] -41.0%
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2017 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members	11,850 475 83 167 \$5.7	3.2% 12,076 487 46 656 \$21.4 \$32,459 61 405	9.9% 13,253 510 42 1,175 \$33.0 \$28,122 43 1,099	10.9% 14,464 529 46 1,549 \$44.3 \$28,599 35 1,887	7.0% 13,891 527 43 1,750 \$48.2 \$25,315 36 2,635	[2017 -	2021] 10.9% 2021] -48.2% 947.9% 745.6% -25.4% 550.6%
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2017 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2018 # of drugs new to EP3 claim experience	11,850 475 83 167 \$5.7	3.2% 12,076 487 46 656 \$21.4 \$32,459 61	9.9% 13,253 510 42 1,175 \$33.0 \$28,122	10.9% 14,464 529 46 1,549 \$44.3 \$28,599	7.0% 13,891 527 43 1,750 \$48.2 \$25,315	[2017 - 52	2021] 10.9% 2021] -48.2% 947.9% 745.6% -25.4% -2021] -41.0% 550.6% 409.2%
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2017 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M)	11,850 475 83 167 \$5.7	3.2% 12,076 487 46 656 \$21.4 \$32,459 61 405 \$10.9	9.9% 13,253 510 42 1,175 \$33.0 \$28,122 43 1,099 \$27.8	10.9% 14,464 529 46 1,549 \$44.3 \$28,599 35 1,887 \$41.4	7.0% 13,891 527 43 1,750 \$48.2 \$25,315 36 2,635 \$55.5	[2017 - 52 [201740 1583 \$42.5 -\$8,636 [201825 2230 \$44.6	2021] 10.9% 2021] -48.2% 947.9% 745.6% -25.4% -2021] -41.0% 550.6% 409.2% -22.2%
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2017 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience	11,850 475 83 167 \$5.7	3.2% 12,076 487 46 656 \$21.4 \$32,459 61 405 \$10.9	9.9% 13,253 510 42 1,175 \$33.0 \$28,122 43 1,099 \$27.8 \$25,260	10.9% 14,464 529 46 1,549 \$44.3 \$28,599 35 1,887 \$41.4 \$21,927	7.0% 13,891 527 43 1,750 \$48.2 \$25,315 36 2,635 \$55.5 \$21,062	[2017 - 52 [201740 1583 \$42.5 -\$8,636 [201825 2230 \$44.6 -\$5,993 [2019 -	2021] -48.2% 947.9% 745.6% -25.4% -2021] -41.0% 550.6% 409.2% -22.2% -2021] -50.0%
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2017 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Claimed by # plan members	11,850 475 83 167 \$5.7	3.2% 12,076 487 46 656 \$21.4 \$32,459 61 405 \$10.9	9.9% 13,253 510 42 1,175 \$33.0 \$28,122 43 1,099 \$27.8 \$25,260 46 177	10.9% 14,464 529 46 1,549 \$44.3 \$28,599 35 1,887 \$41.4 \$21,927	7.0% 13,891 527 43 1,750 \$48.2 \$25,315 36 2,635 \$55.5 \$21,062	[2017 - 52 [201740 1583 \$42.5 -\$8,636 [201825 2230 \$44.6 -\$5,993 [201923 557	2021] -48.2% 947.9% 745.6% -25.4% -2021] -41.0% 550.6% 409.2% -2021] -50.0% 314.7%
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient Al) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2017 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M)	11,850 475 83 167 \$5.7	3.2% 12,076 487 46 656 \$21.4 \$32,459 61 405 \$10.9	9.9% 13,253 510 42 1,175 \$33.0 \$28,122 43 1,099 \$27.8 \$25,260 46 177 \$9.2	10.9% 14,464 529 46 1,549 \$44.3 \$28,599 35 1,887 \$41.4 \$21,927 24 529 \$28.0	7.0% 13,891 527 43 1,750 \$48.2 \$25,315 36 2,635 \$55.5 \$21,062 23 734 \$35.1	[2017 - 52 [201740 1583 \$42.5 -\$8,636 [201825 2230 \$44.6 -\$5,993 [2019 -	2021] -48.2% 947.9% 745.6% -25.4% -2021] -41.0% 550.6% 409.2% -22.2% -314.7% 281.5%
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2017 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020	11,850 475 83 167 \$5.7	3.2% 12,076 487 46 656 \$21.4 \$32,459 61 405 \$10.9	9.9% 13,253 510 42 1,175 \$33.0 \$28,122 43 1,099 \$27.8 \$25,260 46 177	10.9% 14,464 529 46 1,549 \$44.3 \$28,599 35 1,887 \$41.4 \$21,927 24 529 \$28.0 \$54,348	7.0% 13,891 527 43 1,750 \$48.2 \$25,315 36 2,635 \$55.5 \$21,062 23 734 \$35.1 \$47,825	[2017 -	2021] -48.2% 947.9% 745.6% -25.4% -2021] -41.0% 550.6% 409.2% -22.2% -314.7% 281.5% -7.4%
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2017 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020 # of drugs new to EP3 claim experience	11,850 475 83 167 \$5.7	3.2% 12,076 487 46 656 \$21.4 \$32,459 61 405 \$10.9	9.9% 13,253 510 42 1,175 \$33.0 \$28,122 43 1,099 \$27.8 \$25,260 46 177 \$9.2	10.9% 14,464 529 46 1,549 \$44.3 \$28,599 35 1,887 \$41.4 \$21,927 24 529 \$28.0 \$54,348	7.0% 13,891 527 43 1,750 \$48.2 \$25,315 36 2,635 \$55.5 \$21,062 23 734 \$35.1 \$47,825	[2017 -	2021] -48.2% 947.9% 745.6% -25.4% -2021] -41.0% 409.2% -22.2% -2021] -50.0% 314.7% -7.4% -2021] -30.9%
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2017 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020 # of drugs new to EP3 claim experience Claimed by # plan members	11,850 475 83 167 \$5.7	3.2% 12,076 487 46 656 \$21.4 \$32,459 61 405 \$10.9	9.9% 13,253 510 42 1,175 \$33.0 \$28,122 43 1,099 \$27.8 \$25,260 46 177 \$9.2	10.9% 14,464 529 46 1,549 \$44.3 \$28,599 35 1,887 \$41.4 \$21,927 24 529 \$28.0 \$54,348	7.0% 13,891 527 43 1,750 \$48.2 \$25,315 36 2,635 \$55.5 \$21,062 23 734 \$35.1 \$47,825	[2017 -	2021] -48.2% 947.9% 745.6% -25.4% -2021] -41.0% 550.6% 409.2% -2021] -50.0% 314.7% 281.5% -7.4% -2021] -30.9% 147.4%
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2017 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020 # of drugs new to EP3 claim experience	11,850 475 83 167 \$5.7	3.2% 12,076 487 46 656 \$21.4 \$32,459 61 405 \$10.9	9.9% 13,253 510 42 1,175 \$33.0 \$28,122 43 1,099 \$27.8 \$25,260 46 177 \$9.2	10.9% 14,464 529 46 1,549 \$44.3 \$28,599 35 1,887 \$41.4 \$21,927 24 529 \$28.0 \$54,348	7.0% 13,891 527 43 1,750 \$48.2 \$25,315 36 2,635 \$55.5 \$21,062 23 734 \$35.1 \$47,825	[2017 -	2021] -48.2% 947.9% 745.6% -25.4% -2021] -41.0% 550.6% 409.2% -2021] -50.0% 314.7% 281.5% -7.4% -2021] -30.9% 147.4% 120.9%
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient Al) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2017 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs to EP3 claim experience Claimed by # plan members Who had drugs that were first paid in 2020 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M)	11,850 475 83 167 \$5.7	3.2% 12,076 487 46 656 \$21.4 \$32,459 61 405 \$10.9	9.9% 13,253 510 42 1,175 \$33.0 \$28,122 43 1,099 \$27.8 \$25,260 46 177 \$9.2	10.9% 14,464 529 46 1,549 \$44.3 \$28,599 35 1,887 \$41.4 \$21,927 24 529 \$28.0 \$54,348 55 209 \$6.7	7.0% 13,891 527 43 1,750 \$48.2 \$25,315 36 2,635 \$55.5 \$21,062 23 734 \$35.1 \$47,825 38 517 \$14.8	[2017 - 52	2021] -48.2% 947.9% 745.6% -25.4% -2021] -41.0% 550.6% 409.2% -2021] -50.0% 314.7% 281.5% -7.4% -2021] -30.9% 147.4% 120.9% -11.0%
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2017 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2021 # of drugs new to EP3 claim experience	11,850 475 83 167 \$5.7	3.2% 12,076 487 46 656 \$21.4 \$32,459 61 405 \$10.9	9.9% 13,253 510 42 1,175 \$33.0 \$28,122 43 1,099 \$27.8 \$25,260 46 177 \$9.2	10.9% 14,464 529 46 1,549 \$44.3 \$28,599 35 1,887 \$41.4 \$21,927 24 529 \$28.0 \$54,348 55 209 \$6.7	7.0% 13,891 527 43 1,750 \$48.2 \$25,315 36 2,635 \$55.5 \$21,062 23 734 \$35.1 \$47,825 38 517 \$14.8 \$28,627	[2017 -	2021] -48.2% 947.9% 745.6% -25.4% -2021] -41.0% 550.6% 409.2% -2021] -50.0% 314.7% 281.5% -7.4% -2021] -30.9% 147.4% 120.9% -11.0%
Tota Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims High cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient Al) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2017 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020 For drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2021	11,850 475 83 167 \$5.7	3.2% 12,076 487 46 656 \$21.4 \$32,459 61 405 \$10.9	9.9% 13,253 510 42 1,175 \$33.0 \$28,122 43 1,099 \$27.8 \$25,260 46 177 \$9.2	10.9% 14,464 529 46 1,549 \$44.3 \$28,599 35 1,887 \$41.4 \$21,927 24 529 \$28.0 \$54,348 55 209 \$6.7	7.0% 13,891 527 43 1,750 \$48.2 \$25,315 36 2,635 \$55.5 \$21,062 23 734 \$35.1 \$47,825 38 517 \$14.8 \$28,627	[2017 -	2021] -48.2% 947.9% 745.6% -25.4% -2021] -41.0% 550.6% 409.2% -2021] -50.0% 314.7% 281.5% -7.4% -2021] -30.9% 147.4% 120.9% -11.0%

		-	-					
	2017	2018	2019	2020	2021	Period Increase (+) / decrease (-)	% Period Increase (+) / decrease (-)	
Industry pool portion shared between CDIPC member companies (a subset of EP3 pooling)								
Industry pool thresholds and pooling maximum								
						[2017 : 2021]		
Initial threshold	\$65,000	\$65,000	\$65,000	\$65,000	\$65,000	\$0	0.0%	
Ongoing threshold and EP3 pooling endpoint	\$32,500	\$32,500	\$32,500	\$32,500	\$32,500	\$0	0.0%	
Pooling maximum	\$500,000	\$500,000	\$500,000	\$500,000	\$500,000	\$0	0.0%	
Industry pool experience ²								
						[2017 : 2021]		
# plan members w/paid claims greater than or equal to "Ongoing Threshold" (OT)	3,795	4,041	4,305	4,749	4,983	1,188	31.3%	
Representing paid claims of \$ (M)	\$223.3	\$238.1	\$259.2	\$300.9	\$312.0	\$88.7	39.7%	
# plan members qualified for industry pooling	449	470	513	637	749	300	66.8%	
% plan members that qualify to pool when paid claims ≥ OT	11.8%	11.6%	11.9%	13.4%	15.0%			
# plan members qualified for 1st year of industry pooling	146	156	172	256	292	146	100.0%	
\$ pooled (M)	\$6.8	\$8.6	\$8.1	\$12.5	\$13.5	\$6.7	98.5%	
# plan members qualified for 2 or more years of industry pooling	303	314	341	381	457	154	50.8%	
\$ pooled (M)	\$12.0	\$12.4	\$14.0	\$16.6	\$21.1	\$9.1	75.8%	

^{1 -} Estimated